# Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

> **NCT04188405** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Myeloid Leukemia
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Ponatinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04188405
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-17
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188405, "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04188405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*